{
    "clinical_study": {
        "@rank": "21725", 
        "arm_group": [
            {
                "arm_group_label": "A(1.2 mg/kg)+RCHOP", 
                "arm_group_type": "Experimental", 
                "description": "Brentuximab vedotin 1.2 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone"
            }, 
            {
                "arm_group_label": "A(1.8 mg/kg)+RCHOP", 
                "arm_group_type": "Experimental", 
                "description": "Brentuximab vedotin 1.8 mg/kg plus rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and efficacy of brentuximab vedotin in\n      combination with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and\n      prednisone) (known as A+RCHOP) in patients with DLBCL that have never been treated.\n      Patients will be randomly assigned in a 1:1 ratio to receive RCHOP together with 1 of 2\n      doses of brentuximab vedotin. Patients will be tested to see if there is a difference in\n      side effects between the 2 groups."
        }, 
        "brief_title": "Study of Brentuximab Vedotin Combined With RCHOP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)", 
        "completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lymphoma, B-cell", 
            "Lymphoma, Large B-cell, Diffuse"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Treatment-naive patients with systemic de novo or transformed diffuse large B cell\n             lymphoma (DLBCL) or follicular non-Hodgkin lymphoma (NHL) grade 3b\n\n          -  International Prognostic Index (IPI) score greater than or equal to 3 for patients\n             greater than 60 years of age or age-adjusted IPI (aaIPI) score of 2 or 3 for patients\n             less than or equal to 60 years of age\n\n          -  Stage IAX (bulk defined as single lymph node mass > 10 cm in diameter), IB-IV disease\n\n          -  Measurable disease of at least 1.5 cm\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2\n\n        Exclusion Criteria:\n\n          -  Previous history of treated indolent lymphoma\n\n          -  History of another primary malignancy that has not been in remission for 3 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925612", 
            "org_study_id": "SGN35-017"
        }, 
        "intervention": [
            {
                "arm_group_label": "A(1.2 mg/kg)+RCHOP", 
                "description": "1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles", 
                "intervention_name": "brentuximab vedotin", 
                "intervention_type": "Drug", 
                "other_name": "Adcetris; SGN-35"
            }, 
            {
                "arm_group_label": "A(1.8 mg/kg)+RCHOP", 
                "description": "1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles", 
                "intervention_name": "brentuximab vedotin", 
                "intervention_type": "Drug", 
                "other_name": "Adcetris; SGN-35"
            }, 
            {
                "arm_group_label": [
                    "A(1.2 mg/kg)+RCHOP", 
                    "A(1.8 mg/kg)+RCHOP"
                ], 
                "description": "375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles", 
                "intervention_name": "rituximab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "A(1.2 mg/kg)+RCHOP", 
                    "A(1.8 mg/kg)+RCHOP"
                ], 
                "description": "1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2mg total)", 
                "intervention_name": "vincristine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "A(1.2 mg/kg)+RCHOP", 
                    "A(1.8 mg/kg)+RCHOP"
                ], 
                "description": "750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles", 
                "intervention_name": "cyclophosphamide", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "A(1.2 mg/kg)+RCHOP", 
                    "A(1.8 mg/kg)+RCHOP"
                ], 
                "description": "100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles", 
                "intervention_name": "prednisone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "A(1.2 mg/kg)+RCHOP", 
                    "A(1.8 mg/kg)+RCHOP"
                ], 
                "description": "50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles", 
                "intervention_name": "doxorubicin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies, Monoclonal", 
                "Cyclophosphamide", 
                "Rituximab", 
                "Doxorubicin", 
                "Prednisone", 
                "Vincristine"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Antibodies, Monoclonal", 
            "Antibody-Drug Conjugate", 
            "Antigens, CD30", 
            "Drug Therapy", 
            "Hematologic Diseases", 
            "Immunotherapy", 
            "Lymphoma, B-cell", 
            "Lymphoma, Large B-cell, Diffuse", 
            "Monomethyl auristatin E"
        ], 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Melissa.Jansky@Mckesson.com", 
                    "last_name": "Melissa Jansky", 
                    "phone": "281-863-6658"
                }, 
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85016"
                    }, 
                    "name": "Arizona Oncology Associates, PC - HAL"
                }, 
                "investigator": {
                    "last_name": "Mahesh Seetharam, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "brbrophy@coh.org", 
                    "last_name": "Brianna Phye", 
                    "phone": "626-256-4673", 
                    "phone_ext": "89448"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010-3000"
                    }, 
                    "name": "City of Hope Department of Hematology and Hematopoietic Cell Transplantation"
                }, 
                "investigator": {
                    "last_name": "Lihua Elizabeth Budde, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sclund@stanford.edu", 
                    "last_name": "Sabata Lund", 
                    "phone": "650-725-6432"
                }, 
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305-5821"
                    }, 
                    "name": "Stanford Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Ranjana Advani, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Mayo Clinic Clinical Trials ReferralOffice", 
                    "phone": "507-538-7623"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "investigator": {
                    "last_name": "Stephen Ansell, M.D. Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ALEY@DOM.wustl.edu", 
                    "last_name": "Amelia Ley", 
                    "phone": "314-747-8084"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine"
                }, 
                "investigator": {
                    "last_name": "Nancy Bartlett, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Melissa.Jansky@Mckesson.com", 
                    "last_name": "Melissa Jansky", 
                    "phone": "281-863-6658"
                }, 
                "facility": {
                    "address": {
                        "city": "Morristown", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "07962"
                    }, 
                    "name": "Hematology and Oncology Associates of Northern New Jersey"
                }, 
                "investigator": {
                    "last_name": "Charles Farber, MD, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "NMerriman@zangcenter.com", 
                    "last_name": "Nancy Merriman", 
                    "phone": "614-383-6236"
                }, 
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43219"
                    }, 
                    "name": "Mid Ohio Oncology/Hematology Inc"
                }, 
                "investigator": {
                    "last_name": "Mark Knapp, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "psanjorjo@mdanderson.org", 
                    "last_name": "Hie Sanjorjo", 
                    "phone": "713-792-4255"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030-4003"
                    }, 
                    "name": "MD Anderson Cancer Center / University of Texas"
                }, 
                "investigator": {
                    "last_name": "Luis Fayad, MD; FACP", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Melissa.Jansky@Mckesson.com", 
                    "last_name": "Melissa Jansky", 
                    "phone": "281-863-6658"
                }, 
                "facility": {
                    "address": {
                        "city": "Tyler", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75702"
                    }, 
                    "name": "Texas Oncology - Tyler"
                }, 
                "investigator": {
                    "last_name": "Habte Yimer, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "karen.pena@hci.utah.edu", 
                    "last_name": "Karen Pena", 
                    "phone": "801-213-4233"
                }, 
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84112-5550"
                    }, 
                    "name": "University of Utah"
                }, 
                "investigator": {
                    "last_name": "Ahmad Halwani, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Melissa.Jansky@Mckesson.com", 
                    "last_name": "Melissa Jansky", 
                    "phone": "281-863-6658"
                }, 
                "facility": {
                    "address": {
                        "city": "Fairfax", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "22031"
                    }, 
                    "name": "Virginia Cancer Specialists, PC"
                }, 
                "investigator": {
                    "last_name": "Dipti Patel-Donnelly, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jscott@vcu.edu", 
                    "last_name": "Jaime Scott", 
                    "phone": "804-628-1909"
                }, 
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23298"
                    }, 
                    "name": "Virginia Commonwealth University Medical Center"
                }, 
                "investigator": {
                    "last_name": "Beata Holkova, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Melissa.Jansky@Mckesson.com", 
                    "last_name": "Melissa Jansky", 
                    "phone": "281-863-6658"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98684"
                    }, 
                    "name": "Northwest Cancer Specialists, P.C."
                }, 
                "investigator": {
                    "last_name": "Kathryn Kolibaba, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Melissa.Jansky@Mckesson.com", 
                    "last_name": "Melissa Jansky", 
                    "phone": "281-863-6658"
                }, 
                "facility": {
                    "address": {
                        "city": "Yakima", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98902"
                    }, 
                    "name": "Yakima Valley Memorial Hospital / North Star Lodge"
                }, 
                "investigator": {
                    "last_name": "Thomas Boyd, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)", 
        "overall_contact": {
            "email": "clinicaltrials@seagen.com", 
            "last_name": "Terri Lowe", 
            "phone": "866-333-7436"
        }, 
        "overall_official": {
            "affiliation": "Seattle Genetics, Inc.", 
            "last_name": "Dana Kennedy, PharmD, BCOP", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Complete remission rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Incidence of laboratory abnormalities", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925612"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Objective response rate", 
                "safety_issue": "No", 
                "time_frame": "Up to 6 months"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Up to approximately 4 years"
            }
        ], 
        "source": "Seattle Genetics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seattle Genetics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}